Trial Profile
An Observational Post-authorization Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of Rivaroxaban (XARELTO) Initiated in Secondary Care for the Prevention of Atherothrombotic Events in Patients Who Have Had Acute Coronary Syndrome in England and Wales
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Dec 2020
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Antiplatelets
- Indications Atherosclerosis
- Focus Therapeutic Use
- Acronyms ROSE ACS
- 23 Apr 2019 Status changed from recruiting to completed.
- 18 Feb 2016 New trial record